Summary
Abbott Laboratories (ABT) reported solid top-line growth for the first quarter of 2019, with net sales increasing by 2.0% year-over-year to $7.535 billion. Excluding the unfavorable impact of foreign exchange, net sales grew by a robust 6.8%, indicating strong underlying performance across its diverse business segments. Diluted earnings per share from continuing operations reached $0.38, a significant increase from $0.23 in the prior year period. The company demonstrated operational improvements, with gross profit margin rising to 51.6% from 50.6% in Q1 2018, primarily due to lower intangible asset amortization. Key growth drivers included the Diagnostics segment, which saw a 4.4% increase in sales (excluding FX), and the Cardiovascular and Neuromodulation segment, up 3.6% (excluding FX), bolstered by strong performance in Electrophysiology, Heart Failure, and Structural Heart products. The Diabetes Care business, a notable contributor within 'Other,' experienced substantial growth of 42.0% (excluding FX), largely driven by the FreeStyle Libre continuous glucose monitoring system. While the Established Pharmaceutical Products segment saw a decline in net sales, this was partially offset by growth in Key Emerging Markets (excluding FX). Financially, Abbott maintained a strong balance sheet, though cash and cash equivalents decreased from the end of 2018, primarily due to debt repayment, dividend payments, and capital expenditures. The company continued its commitment to shareholder returns, increasing its quarterly dividend by 14% year-over-year. Abbott also highlighted its proactive approach to managing financial risks through various hedging strategies.
Financial Highlights
52 data points| Revenue | $7.54B |
| Cost of Revenue | $3.16B |
| Gross Profit | $3.89B |
| R&D Expenses | $672.00M |
| SG&A Expenses | $2.48B |
| Operating Expenses | $6.80B |
| Operating Income | $739.00M |
| Interest Expense | $171.00M |
| Net Income | $672.00M |
| EPS (Basic) | $0.38 |
| EPS (Diluted) | $0.38 |
| Shares Outstanding (Basic) | 1.76B |
| Shares Outstanding (Diluted) | 1.78B |
Key Highlights
- 1Net sales increased by 2.0% to $7.535 billion, with an organic growth of 6.8% (excluding foreign exchange impact), demonstrating consistent business momentum.
- 2Diluted earnings per share (EPS) from continuing operations grew significantly to $0.38, up from $0.23 in the prior year quarter, indicating improved profitability.
- 3The Cardiovascular and Neuromodulation segment reported a 3.6% organic sales increase, driven by strong performance in Electrophysiology, Heart Failure (HeartMate 3®), and Structural Heart (MitraClip®) products.
- 4The Diagnostics segment achieved 4.4% organic sales growth, supported by the adoption of the Alinity® family of diagnostic instruments.
- 5Diabetes Care, a key part of the 'Other' segment, saw remarkable 42.0% organic sales growth, primarily fueled by the FreeStyle Libre continuous glucose monitoring system, which grew 80.1% organically.
- 6Gross profit margin improved to 51.6% from 50.6% in the prior year period, benefiting from lower amortization of intangible assets.
- 7Abbott increased its quarterly dividend by 14% to $0.32 per share, reflecting confidence in its financial health and commitment to shareholder returns.